(CNN) — A three-year study of tirzepatide – a medication approved in the US as Mounjaro for diabetes and Zepbound for weight loss – found that when adults who had prediabetes and obesity or overweight used it weekly, it lowered their risk of progression to diabetes by 94% compared with a placebo, according to drugmaker Eli Lilly. Furthermore, as clinical trials continue, the impact of Tirzepatide diabetes reduction will likely expand. #TirzepatideDiabetesReduction
The company reported Tuesday that a 15-milligram dose led to a nearly 23% average decrease in body weight. In contrast, those receiving a placebo saw only a 2.1% reduction.
During a 17-week off-treatment follow-up period, people who had stopped using tirzepatide began to regain weight, Lilly said in a news release, and there was “some increase in the progression to type 2 diabetes.”
“The most frequently reported adverse events were typically gastrointestinal-related and generally mild to moderate in severity,” Lilly said. “The most common gastrointestinal-related adverse events for patients treated with tirzepatide were diarrhea, nausea, constipation and vomiting.”
Prediabetes is a condition where blood sugar levels are higher than normal but not high enough for a diabetes diagnosis. It affects about 1 in 3 adults in the US, totaling 84 million people. Approximately 70% of those with prediabetes will eventually be diagnosed with diabetes, making weight loss a crucial management tool. #TirzepatideDiabetesReduction
Moreover, Tirzepatide diabetes reduction is not just about numbers. It represents a vital step forward in preventing the onset of diabetes in vulnerable populations. Consequently, this treatment could dramatically change how we approach diabetes prevention.
read more
